Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
180 Life Sciences Corp. (Name of Issuer) |
Common Stock, $0.0001 par value (Title of Class of Securities) |
68236V302 (CUSIP Number) |
04/09/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 68236V302 |
1 | Names of Reporting Persons
AMTRUST FINANCIAL SERVICES, INC. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
509,707.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
9.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13G
|
CUSIP No. | 68236V302 |
1 | Names of Reporting Persons
AMTRUST INTERNATIONAL UNDERWRITERS DAC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
IRELAND
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
509,707.00 | 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||
11 | Percent of class represented by amount in row (9)
9.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IC |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
180 Life Sciences Corp. | |
(b) | Address of issuer's principal executive offices:
3000 EL CAMINO REAL, BLDG 4, STE 200 Palo Alto, CA, 94306 | |
Item 2. | ||
(a) | Name of person filing:
The persons filing this statement are AmTrust Financial Services, Inc. ("AFSI") and AmTrust International Underwriters DAC ("AIUDAC", together with AFSI, the "Reporting Persons"). AFSI has the sole voting and dispositive power with regard to 509,707 of the issuer's shares of common stock. AIUDAC is a subsidiary of AFSI. | |
(b) | Address or principal business office or, if none, residence:
The principal business address of the AFSI is 59 Maiden Lane, 43rd Floor, New York, NY 10038. The registered address of AIUDAC is 6-8 College Green, Dublin 2, D02 VP48. | |
(c) | Citizenship:
AFSI is incorporated in Delaware. AIUDAC is incorporated in Ireland. | |
(d) | Title of class of securities:
Common Stock, $0.0001 par value | |
(e) | CUSIP No.:
68236V302 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
AFSI has the sole voting and dispositive power with regard to 509,707 of the issuer's shares of common stock and is acting as an advisor on behalf of AIUDAC. AIUDAC is a subsidiary of AFSI. | |
(b) | Percent of class:
As of April 9, 2025, the Reporting Persons may be deemed to beneficially own in the aggregate 509,707 of the issuer's shares of common stock, representing approximately 9.8% of the issuer's outstanding shares (based on 5,185,780, shares outstanding as of March 31, 2025, as disclosed in the issuer's Annual Report on Form 10-K for the year ended December 31, 2024.) %
| |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein. | ||
(ii) Shared power to vote or to direct the vote:
The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein. | ||
(iii) Sole power to dispose or to direct the disposition of:
The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein. | ||
(iv) Shared power to dispose or to direct the disposition of:
The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein. | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
Exhibit Information
|
99.1 - Joint Filing Agreement |